Scientists Create Self-Replicating T Cells for Cancer Treatment

Key Takeaways

1. UCLA researchers developed a “tandem” therapy using reprogrammed stem cells to provide a continuous source of immune cells to fight cancer.
2. Current T-cell therapies often lose effectiveness over time due to fatigue; the new method addresses this by providing two separate cell infusions.
3. Hematopoietic stem cells (HSCs) serve as a self-replenishing source of T cells, maintaining their tumor-targeting abilities without fatigue.
4. The study indicates a potential for long-term immune defense against cancer, suggesting future treatment options may prevent recurrence.
5. The modified stem cells include a safety mechanism (suicide gene sr39TK) that allows for monitoring and elimination of cells if adverse reactions occur.

In a groundbreaking clinical study, researchers from UCLA have successfully utilized a patient’s own reprogrammed stem cells to establish a continuous, internal source of immune cells that can kill cancer. This research, shared in Nature Communications, introduces an innovative “tandem” therapy aimed at tackling a major issue in cancer immunotherapy — the limited duration of T-cell treatments.

Current Limitations in T-cell Therapy

Presently, T-cell therapies can produce a strong initial reaction; however, the modified cells sometimes become fatigued and lose their effectiveness over time. The new method from UCLA, which was evaluated in a Phase I clinical trial, tackles this problem by administering two distinct cell infusions. Initially, patients get a standard dose of T cells that are engineered to target tumors expressing the NY-ESO-1 antigen. The following day, they receive another infusion of their genetically altered blood-forming cells, scientifically referred to as hematopoietic stem cells (HSCs).

Long-Term Immune Response

These HSCs serve as a sustainable, self-replenishing source, generating fresh T cells right within the patient’s body. Importantly, the study indicates that these new T-cell “descendants” demonstrated tumor-targeting abilities with “no signs of anergy or fatigue,” directly addressing the main drawback of current therapies.

“We’ve demonstrated that we can reprogram a patient’s own stem cells to establish a renewable immune defense against cancer. While it’s not a complete cure yet… it suggests a future where we not only treat cancer but also prevent its recurrence.” — Dr. Theodore Scott Nowicki, one of the study’s lead authors.

Safety Features of Engineered Cells

The modified stem cells also come with an integrated safety mechanism: a “suicide gene” known as sr39TK. This gene enables physicians to monitor the cells within the body through PET scans and provides a method to eliminate them if any unforeseen toxic reactions arise.

Source:
Link